We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Inflammatory polyarthropathies
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The development of inflammatory arthritis (IA) involves a presumed multi-step sequential process that ultimately results in chronic, destructive joint disease. The ultimate IA phenotype, however, can be varied, with joint involvement ranging from mono-arthritis to poly-articular disease. Joint involvement can entail synovitis with or without erosive bony change, the latter frequently deteriorating over time.
The course of the disease may be marked by periods of disease activity and remission which varies between patients. In terms of immunological status, patients may be sero-negative (ie have no auto-antibodies) or express a variety of antibodies associated with inflammatory disease. Variable combinations of all these characteristics create a broad heterogeneity, which is partly manifested by differences in disease outcomes, spanning from disease remission to severe disability and early mortality. The ability to predict disease progression and treatment response within this heterogeneous group is still lacking. There is evidence, however, supporting treatment at the earliest stage possible in a patient’s presentation (the so-called ‘window of opportunity’) as early intervention reduces the chance of developing erosive disease and functional impairment.
The main challenge therefore is to identify subjects at risk of developing inflammatory arthritis at the earliest stage. By correlating clinical information obtained in IA patients with immunological data obtained from the analysis of serum, blood and histological samples as well as therapeutic response clinical data, we aim to identify predictive and prognostic biomarkers for the development of persistent, destructive arthritis and to differentiate subsets of arthritis with distinct pathophysiology that allows optimized targeting of treatment.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
For patients: 1. Age less than 18 years 2. Lack of capacity to give informed consent 3. For the MRI imaging component, the following exclusions will apply: pacemakers, surgical clips within the head, certain inner ear implants, neuroelectrical stimulators or metal fragments within the eye or head, eGFR < 45 ml/min/1.73 m2 4. Pregnancy or breastfeeding For controls: 1. Age less than 18 years 2. Lack of capacity to give informed consent 3. For the MRI imaging component, the following exclusions will apply: pacemakers, surgical clips within the head, certain inner ear implants, neuroelectrical stimulators or metal fragments within the eye or head 4. Pregnancy or breastfeeding
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Leeds and funded by VERSUS ARTHRITIS .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 8640
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
